Revolution Medicines to Unveil New Phase 1 & 2 Data for Key Oncology Drugs at AACR Meeting
RVMD has more than doubled off its 52-week low of $29.17.
Summary
Revolution Medicines announced it will present significant new clinical data for its RAS(ON) targeted oncology pipeline at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The presentations will feature new Phase 1 data for zoldonrasib, a RAS(ON) G12D-selective inhibitor, in non-small cell lung cancer during a plenary session. Additionally, two Phase 1/2 datasets for daraxonrasib, a RAS(ON) multi-selective inhibitor, in metastatic pancreatic cancer will be highlighted, including monotherapy and combination data, with one in a mini-symposium. A poster for the Phase 3 RASolve 301 study of daraxonrasib in RAS-mutant NSCLC will also be presented. This announcement is a highly material event for Revolution Medicines, providing a critical upcoming catalyst for its lead pipeline assets. Professional traders will be closely monitoring these presentations for efficacy and safety data, which could significantly impact the company's valuation and future development trajectory. The AACR meeting, taking place April 17–22, 2026, represents a key period for potential stock movement.
At the time of this announcement, RVMD was trading at $98.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.6B. The 52-week trading range was $29.17 to $124.49. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.